Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation  Kirsten M. Williams, Guang-Shing Cheng, Iskra Pusic, Madan Jagasia, Linda Burns, Vincent T. Ho, Joseph Pidala, Jeanne Palmer, Laura Johnston, Sebastian Mayer, Jason W. Chien, David A. Jacobsohn, Steven Z. Pavletic, Paul J. Martin, Barry E. Storer, Yoshihiro Inamoto, Xiaoyu Chai, Mary E.D. Flowers, Stephanie J. Lee  Biology of Blood and Marrow Transplantation  Volume 22, Issue 4, Pages 710-716 (April 2016) DOI: 10.1016/j.bbmt.2015.10.009 Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 FAM stabilizes FEV1 in the majority of patients at 3 months. (A) Eighty-three percent of patients had study-defined documented success on 3 month PFTs, 3% percent had documented failure at 3 months (10% or more absolute decline in percent predicted FEV1), and 5 (14%) were missing 3-month PFTs. These 5 patients were later reclassified as 1 failure (no PFTs available at 2, 3, or 6 months) and 4 successes (3 based on 2-month PFTs and 1 on the basis of 2- or 6-month PFTs). (B) Proportion of patients (n = 30 evaluable at 3 months) with greater or equal to 5% improvement, greater than or equal to 5% decline (and including those who were not able to be evaluated as these failures), or less than 5% change (stability). Biology of Blood and Marrow Transplantation 2016 22, 710-716DOI: (10.1016/j.bbmt.2015.10.009) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Trajectory of FEV1 over time after FAM exposure. Individual percent predicted FEV1 values are graphed as a function of time for each patient. The bold line represents the median of the cohort. Biology of Blood and Marrow Transplantation 2016 22, 710-716DOI: (10.1016/j.bbmt.2015.10.009) Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions